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Abstract
Cancer cells need to meet the metabolic demands of rapid cell growth within a continually
changing microenvironment. Genetic mechanisms for reprogramming cellular metabolism toward
proliferative, pro-survival pathways are well-reported. However, post-translational mechanisms,
which would enable more rapid, reversible adaptations of cellular metabolism in response to
protein signaling or environmental sensing systems, are less well understood. Here we
demonstrate that the post-translational modification O-linked β-N-acetylglucosamine (O-GlcNAc)
is a key metabolic regulator of glucose metabolism. O-GlcNAc is dynamically induced at Ser529
of phosphofructokinase 1 (PFK1) in response to hypoxia. Glycosylation inhibits PFK1 activity and
redirects the flux of glucose from glycolysis through the pentose phosphate pathway (PPP),
thereby conferring a selective growth advantage to cancer cells. Blocking glycosylation of PFK1
at Ser529 reduced cancer cell proliferation in vitro and impaired tumor formation in vivo. These
studies reveal an unexpected mechanism for the regulation of metabolic enzymes and pathways,
and pinpoint a new therapeutic approach for combating cancer.
Rapid physiological response is critical for the growth of tumors, which must satisfy the
metabolic demands of increased cell proliferation in the face of a dynamically changing
microenvironment. It is now well established that cancer cells undergo significant
reprogramming of their cellular metabolism to facilitate the efficient generation of ATP,
nucleotide and lipid precursors for macromolecular synthesis, and NADPH to maintain
redox homeostasis (1-5). Mutations in tumor suppressors and oncogenic pathways are
known to contribute to these altered metabolic phenotypes (1, 6-8), but such changes
constitute a slower, more permanent response compared to the rapid, reversible responses
needed to adapt to tumor microenvironments in vivo. Integration of metabolic flux with
rapid-response mechanisms, such as phosphorylation or other post-translational
mechanisms, would provide cancer cells with the ability to regulate cellular physiology
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rapidly and reversibly in response to a wide range of signals. However, the post-translational
mechanisms that connect signaling pathways to the reprogramming of metabolic flux toward
proliferative, pro-survival pathways are poorly understood.
The dynamic post-translational modification O-linked β-N-acetylglucosamine (O-GlcNAc)
glycosylation serves as a nutrient sensor to couple metabolic status to the regulation of a
wide variety of signaling pathways (9-12). O-GlcNAc transferase (OGT) catalyzes the
transfer of N-acetylglucosamine from uridine diphospho-N-acetylglucosamine (UDP-
GlcNAc) to serine or threonine residues of many intracellular proteins, including signaling
proteins important for insulin resistance (12), oncogenes and tumor suppressors (13,14), and
transcriptional co-activators that control gluconeogenesis (15). O-GlcNAc levels can be
induced within minutes (16), accumulate on the minute-to-hours time scale (17), and are
dynamically altered by changes in the cellular concentration of UDP-GlcNAc (9-11). UDP-
GlcNAc constitutes the physical integration of several key metabolites, including glucose
from glycolysis and carbon supply, glutamine from TCA anapleurosis and nitrogen supply,
acetyl-CoA from fatty acid metabolism and NADPH supply, uridine from nucleotide
biosynthesis, and ATP from energy charge and oxygen availability (18,19). As such, UDP-
GlcNAc may serve as a functional reporter of the status of many important metabolic
pathways. Indeed, recent studies have shown that UDP-GlcNAc and the hexosamine
biosynthesis pathway couple growth factor-induced glutamine uptake to glucose metabolism
via N-glycosylation of the IL-3 receptor (18). However, the downstream fates of UDP-
GlcNAc, particularly the functional consequences of dynamic O-GlcNAc glycosylation in
the regulation of cancer cell metabolism, remain unknown.
To gain insight into whether cytoplasmic O-GlcNAc glycosylation might directly couple
nutrient sensing to cellular metabolism, we modulated O-GlcNAc levels and measured the
effects on aerobic glycolysis. Global O-GlcNAc levels were enhanced by 2-4 fold in the
human lung cancer cell line H1299 by overexpression of OGT or by pharmacological
inhibition of β-N-acetylglucosaminidase (O-GlcNAcase or OGA), the glycosidase that
removes O-GlcNAc (Fig. 1A). Increasing O-GlcNAc levels resulted in decreased rates of
glucose metabolism (by 23.7±6.7% PUGNAc, 34.6±8.0% OGT overexp), as measured by
the conversion of 5-3H-glucose to 3H2O, which is catalyzed by enolase in the penultimate
step of glycolysis (Fig. 1B). Enhancing O-GlcNAc glycosylation also led to reduced lactate
production (by 31.3±11.5% PUGNAc, 40.1±8.2% OGT overexp) and lowered cellular ATP
levels (by 20.2±6.5% PUGNAc, 22.4±3.7% OGT overexp). Similar effects were observed in
other cells, including invasive A549 cancer cells and 293T cells (fig. S1). To confirm that
the effects result from the OGT-dependent glycosylation of protein substrates, we produced
stable knockdown of OGT in H1299 or 293T cells using shRNA (Fig. 1C and fig. S2).
Inhibition of OGA in these OGT-deficient cells had no significant effect on glucose
metabolism, lactate production or ATP production (Fig. 1C and fig. S2), suggesting the
direct involvement of OGT in the regulation of carbon flow through the glycolytic pathway.
Our proteomics studies had revealed that nearly all of the enzymes in the glycolytic pathway
are potential substrates for OGT (20). To determine which enzyme activities are regulated,
we modulated O-GlcNAc levels in 293T cells as before and measured the activity of each
enzyme in the pathway. Increasing O-GlcNAc levels significantly decreased (by 15.4±5.8%
PUGNAc, 22.6±3.5% OGT-overexp) the activity of phosphofructokinase 1 (PFK1), a major
regulatory enzyme long established to control flux through the glycolytic pathway (21) (Fig.
1D). No change in the protein expression levels of PFK1 was observed (fig. S2), indicating
that the decrease in activity was not due to reduced PFK1 expression. By contrast,
enhancing O-GlcNAc levels had only modest effects on other key regulatory points in the
pathway, including hexokinase, phosphoglycerate kinase and pyruvate kinase (fig. S3), and
no appreciable effect on other glycolytic enzymes.
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To establish that PFK1 is directly O-GlcNAc glycosylated, we used a chemoenzymatic
approach (20) whereby O-GlcNAc-modified proteins from 293T cell lysates were
selectively labeled with a non-natural azido-sugar using an exogenous glycosyltransferase
enzyme, biotinylated using [3+2] azide-alkyne cycloaddition chemistry, and captured with
streptavidin-agarose beads (fig. S4). Immunoblotting of the captured proteins with an anti-
PFK1 antibody showed a strong signal indicative of O-GlcNAc glycosylation of PFK1 (Fig.
1E), which could be further enhanced by overexpression of OGT (fig. S4). We also
generated a stable cell line expressing Flag-tagged PFK1 and chemoenzymatically labeled
the lysate with a 5-kDa polyethylene glycol (PEG) mass tag to shift the molecular mass of
the O-GlcNAc-modified species (22). Immunoblotting with an anti-Flag antibody enabled
direct visualization of both the non-glycosylated and glycosylated species of Flag-PFK1
(Fig. 1F). Notably, the population of glycosylated PFK1 significantly increased by 15-fold
or 6-fold upon OGT overexpression or OGA inhibition, respectively, indicating that
glycosylation of PFK1 is reversibly and dynamically regulated by the expression levels or
activities of these enzymes. A similar pattern of PFK1 glycosylation was observed in
multiple human solid tumor lines (LNCaP, MCF-7, MDA-mb-231, MCF-10-DCIS.com, and
MCF-10AT; fig. S5). Moreover, PFK1 glycosylation was induced in a time-dependent
manner under hypoxic conditions or when cells were subjected to glucose deprivation (Fig.
1G). Consistent with previous reports that OGT expression and O-GlcNAc levels are
induced by glucose deprivation and other forms of cell stress (23,24), we observed modest
increases in OGT expression levels but found no detectable changes in OGA or PFK1
expression (fig. S6). Thus, PFK1 is O-GlcNAc glycosylated in cancer cells and
glycosylation is triggered under conditions associated with tumorigenesis and rapid tumor
growth.
To identify the glycosylation site(s) on PFK1, FLAG-tagged PFK1 and OGT were
transiently co-expressed in 293T cells. After immunoprecipitation and proteolytic digestion
of PFK1, O-GlcNAc-modified peptides were enriched by WGA lectin affinity
chromatography and subjected to electron transfer dissociation mass spectrometry (ETD-
MS) analysis. We identified a single site of glycosylation at Ser529, a highly conserved
residue important for allosteric regulation of PFK1 by fructose-2,6-bisphosphate (F-2,6-BP)
(25) (Fig. 2A and fig. S7). F-2,6-BP is the dominant modulator of PFK1 at the high ATP
concentrations (2-5 mM) found in cancer cells (26). Mutation of Ser529 to alanine (S529A)
abolished the glycosylation of PFK1 in 293T cells, whereas alanine mutation of the
neighboring residue Thr527 had no effect, indicating that Ser529 is the specific, major site
of O-GlcNAc glycosylation on PFK1 (Fig. 2B).
Although no structure for human PFK1 is available, the enzyme shares 82% sequence
identity within the F-2,6-BP binding site with S. cerevisiae PFK, which was recently co-
crystallized with F-2,6-BP (27), and shares 97% sequence identity with rabbit PFK1, whose
apo-structure has been solved (27). To gain insight into the potential effects of glycosylation
on F-2,6-BP binding, we used the S. cerevisiae structure to generate a homology model of
rabbit PFK1 complexed to F-2,6-BP (Fig. 2C). The rmsd between the rabbit and yeast
structures was only 1.70 Å, and the 2-phosphate phosphorus of F-2,6-BP in the yeast
structure aligned closely with the phosphorus atom of a phosphate ion in the rabbit structure
(rmsd 0.25 Å). Moreover, Arg566, Arg655 and His661, which have been shown by
mutagenesis to be part of the F-2,6-BP binding site of human PFK1 (25), are found in the
predicted rabbit F-2,6-BP binding site. Importantly, we found that Ser529 (Ser530 in rabbit)
forms a hydrogen bond with the phosphate ion in the rabbit structure and with the 2-
phosphate group of F-2,6-BP in the homology model, suggesting that the addition of a
GlcNAc moiety to Ser529 may block the ability of PFK1 to interact with the allosteric
activator. As further confirmation, we modeled the O-GlcNAc modification on rabbit PFK.
The five lowest energy structures showed similar O-GlcNAc conformations, with an average
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rmsd of 0.59 ± 0.42 Å compared to the lowest energy structure. In all cases, the O-GlcNAc
moiety occupied the F-2,6-BP-binding pocket and made multiple hydrogen-bonding
contacts with the protein (Fig. 2D), suggesting that glycosylation of Ser529 sterically
occludes binding of F-2,6-BP. In contrast to F-2,6-BP, the O-GlcNAc residue made
hydrogen-bonding contacts with only the subunit to which it was covalently bound and
formed no hydrogen bonds with the second PFK subunit. Interactions between F-2,6-BP and
the two subunits have been proposed to stabilize the PFK dimer in the active conformation
(27) and promote the formation of PFK tetramers (25). Thus, our structural models suggest
that O-GlcNAc glycosylation inhibits PFK1 activity by blocking the binding of F-2,6-BP
and possibly perturbing the oligomerization of PFK1 subunits.
We examined the effects of O-GlcNAc glycosylation on PFK1 activity by comparing two
forms of PFK1 with different levels of glycosylation. Specifically, we tested human Flag-
tagged PFK1 expressed in 293T cells in the presence or absence of cellular treatments that
enhanced PFK1 glycosylation levels. Increasing O-GlcNAc levels on PFK1 resulted in a 35
± 5% decrease in PFK1 activity (Fig. 2E and fig. S8). By comparison, the same treatments
produced no significant change in activity when Ser529 was mutated to alanine. Thus,
glycosylation exerts a strong inhibitory effect on PFK1 activity, and this effect is rescued by
the S529A mutation. Interestingly, the activity of S529A PFK1 was modestly impaired at
lower F-2,6-BP concentrations (fig. S9), consistent with the importance of Ser529 in
recognition of the allosteric activator. Glycosylation also inhibited PFK1 activity across a
wide ATP concentration range both in the presence and absence of F-2,6-BP (fig. S10).
These results demonstrate that O-GlcNAc glycosylation of PFK1 at S529 inhibits PFK1
activity, providing a novel mechanism to overcome the allosteric regulation of PFK1 by
small molecules.
F-2,6-BP slows the dissociation of high molecular weight complexes of PFK1 and promotes
the association of PFK1 into larger aggregates with enhanced catalytic activity (21). To
probe whether glycosylation also affects the oligomerization of PFK1, Flag-tagged PFK1
was expressed in 293T cells in the presence or absence of OGT, immunopurified and
analyzed by native gel electrophoresis. Upon co-expression with OGT, a significant fraction
of PFK1 exhibited greater mobility, indicating formation of a lower molecular weight
complex (Fig. 2F). A similar shift in mobility was observed when PFK1 glycosylation levels
were increased by treating cells with PUGNAc. Heat denaturation of PFK1 from untreated
cells produced a complex of similar mobility, suggesting that this complex represents a
lower oligomeric state of PFK1 (fig. S11). To provide further confirmation that
glycosylation impairs the association of PFK1 subunits, we examined the ability of Flag-
tagged PFK1 to co-immunoprecipitate endogenous PFK1. We found that overexpression of
OGT hindered the co-immunoprecipitation of PFK1 subunits, and this effect was blocked by
alanine mutation of Ser529 (Fig. 2G). Cumulatively, these results provide strong evidence
that O-GlcNAc glycosylation not only inhibits the activity of PFK1, but also perturbs the
equilibrium between different oligomeric forms to favor a lower oligomeric state. Such a
mechanism would enable glycosylated PFK to exert significant effects on the overall PFK1
activity by controlling the balance between high and low activity states.
To create a system to study the functional consequences of Ser529 glycosylation on cellular
metabolism, we knocked down endogenous PFK1 and stably expressed Flag-tagged WT or
S529A PFK1 in H1299 cells (referred to as WT PFK1 or S529A PFK1 knock-in cells; Fig.
3A). When glycosylation of WT PFK1 was enhanced by overexpression of OGT, the cells
exhibited reduced glycolysis and lactate production (by 25.4±5.7% and 37.5±7.3%,
respectively; Fig. 3B), consistent with earlier findings (Fig. 1B and fig. S1). Importantly, no
change in glycolytic rate or lactate production was observed with the S529A mutant upon
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OGT overexpression, indicating that OGT inhibits glycolysis specifically through
glycosylation of PFK1 at Ser529.
Suppressing glycolysis via inhibition of PFK1 could lead to the accumulation of glycolytic
intermediates and redirect metabolic flux down the oxidative pentose phosphate pathway
(PPP). This shift would provide cells with pentose sugars for nucleotides and nucleic acid
biosynthesis, as well as reducing equivalents from NADPH to combat oxidative stress
(28,29). Increased flux through the oxidative PPP pathway, as measured by the amount of
released 14CO2 from [1-14C]-glucose, was indeed observed when O-GlcNAc levels were
enhanced by OGT overexpression in WT PFK1 knock-in cells (Fig. 3C). In contrast, PPP
flux remained unaffected by OGT overexpression in S529A PFK1 knock-in cells. The
observed increase in PPP activity for S529A PFK1 compared to WT PFK1 knock-in cells
was likely due to the modest inhibitory effects of the S529A mutation on PFK1 activity (fig.
S9). These results were further confirmed by metabolically labeling the cells with [1,2-13C]-
glucose and measuring the relative isotopic enrichment of doubly versus singly [13C]-
labeled lactate, pyruvate, and 3-phosphoglycerate by LC-MS analysis, an established
method that directly tracks labeled glucose flux simultaneously through glycolysis and the
PPP (30). Specifically, a 2.1-fold induction in PPP flux was observed in WT PFK1 knock-in
cells upon overexpression of OGT, whereas cells expressing the S529A mutant showed no
change (Fig. 3D). Thus, the alteration in pathway flux in a cellular context has been
demonstrated using two independent metabolic assays, linking the specific molecular
alteration in PFK1 to whole-cell re-regulation of at least two essential pathways, glycolysis
and the PPP.
Flux through the PPP generates NADPH, which maintains a pool of reduced glutathione
(GSH) and plays an important role in combating reactive oxygen species (ROS)-mediated
cell death (31,32). Consistent with increased flux through the PPP, enhancing O-GlcNAc
levels in WT PFK1 knock-in cells resulted in 1.6-fold and 4-fold inductions in NADPH and
GSH levels, respectively (Fig. 3E). Blocking glycosylation of PFK1 at Ser529 fully
prevented the increase in NADPH and partially prevented the increase in GSH,
demonstrating the importance of O-GlcNAc glycosylation at Ser529. Consistent with these
observations, untargeted metabolite profiling by high-resolution flow-injection mass
spectrometry (33) revealed enhanced steady-state concentrations of GSH, amino acids, and
nucleotide precursors in WT PFK1 knock-in cells relative to S529A PFK1 knock-in cells
(table S1). Furthermore, we found significant reductions in NADPH and GSH levels in
S529A PFK1 knock-in cells compared to WT PFK1 knock-in cells under hypoxic conditions
(Fig. 3F), suggesting that S529 has a major role in responding to hypoxia and that blocking
PFK1 glycosylation can restore metabolic flux through the glycolysis pathway. To confirm
further that glycosylation of PFK1 confers a protective advantage to cancer cells, we
measured the sensitivity of H1299 cells to ROS-mediated cell death upon overexpression of
OGT. Enhancing O-GlcNAc levels prevented the increase in ROS levels induced by diamide
(Fig. 3G) and protected the cells from hydrogen peroxide-induced cell death (Fig. 3H).
Taken together, the results indicate that increases in PPP flux induced by PFK1
glycosylation have significant consequences for promoting cancer cell survival.
We next investigated the effects of these glycosylation-induced metabolic changes on cell
growth. Cells expressing the S529A mutant showed a significantly slower proliferation rate
compared to cells expressing WT PFK1 under hypoxic conditions, consistent with decreased
flux through the PPP (Fig. 4A). The proliferation rate of WT PFK1-expressing cells was
enhanced further upon OGT overexpression, while importantly, that of S529A PFK1-
expressing cells was unchanged. To confirm that glycosylation of endogenous PFK1 plays a
specific role, we examined the proliferation of OGT overexpression or knockdown cells
under hypoxic conditions. OGT overexpression enhanced, while OGT knockdown reduced,
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cell proliferation under hypoxic conditions (Fig. 4B). Knocking down PFK1 abolished these
effects, indicating that O-GlcNAc glycosylation stimulates cell proliferation through a
PFK1-dependent mechanism. Thus, glycosylation of PFK1 at Ser529 promotes cell
proliferation in vitro, and blocking glycosylation reverses the effect.
To determine whether PFK1 glycosylation is important for tumor growth and survival in
vivo, we injected immunocompromised mice with WT PFK1 or S529A PFK1 knock-in cells
in the presence or absence of OGT overexpression (fig. S12) and assayed for tumor
formation. Mice injected with S529A PFK1 knock-in cells showed a significant decrease in
tumor mass compared to mice injected with WT PFK1 knock-in cells (Fig. 4C). Moreover,
overexpression of OGT in WT PFK1 knock-in cells led to enhanced tumor growth, but had
no significant effect on S529A PFK1 knock-in cells. Western blot analysis confirmed that
the Flag-tagged WT or S529A PFK1 proteins were retained in the tumors and that WT
PFK1 was O-GlcNAc-modified in the tumors (fig. S12). These results are consistent with
the in vitro cell proliferation data and demonstrate that glycosylation of PFK1 at Ser529
provides a critical growth advantage to tumors in vivo.
Our studies reveal an unexpected mechanism for the regulation of metabolic enzymes –
namely, post-translational modification of allosteric sites. Unlike the often-transient
interactions of allosteric modulators, the covalent nature of post-translational modifications
allows for distinct temporal control, while maintaining the ability to respond reversibly and
dynamically to the cell’s overall physiological status. Regulation of allosteric sites via post-
translational modifications also opens up the opportunity to redirect metabolic flux in
response to specific signaling pathways, such as growth factor activation or oxidative stress.
Compared to well-established genetic mechanisms for reprogramming metabolic flux
(5,34-37), post-translational modifications exert their control on a much faster time-scale,
endowing cells with more flexibility to adapt to a constantly changing microenvironment.
Through their ability to reversibly modulate a selected subpopulation of the enzyme, post-
translational modifications may also allow for more precise control over metabolic enzymes
and pathways. Given that many metabolic enzymes have been recently shown to be
acetylated, phosphorylated and glycosylated (20,38-39), the post-translational modulation of
allosteric sites may represent a general mechanism for integrating the cell’s metabolic
response with its protein signaling, epigenetic or environmental sensing systems.
Here we demonstrate that O-GlcNAc glycosylation directly regulates glycolysis and re-
routes metabolic flux through pathways critical for cancer cell proliferation and survival.
Although numerous studies have shown that O-GlcNAc functions as a metabolic sensor
(9-12), our study establishes the first direct role for O-GlcNAc as a central regulator of
cellular metabolism. These results suggest the existence of dynamic interaction networks,
whereby O-GlcNAc simultaneously senses and modulates metabolic flow through essential
pathways. As UDP-GlcNAc represents a key point of pathway integration and enables the
cell to monitor the balance between glucose and glutamine uptake (18,19), O-GlcNAc
glycosylation of PFK1 may provide a mechanism to link the availability of both carbon and
nitrogen sources for the cell to the production of metabolites necessary for sustaining rapid
cell growth.
Under conditions of oxidative stress, O-GlcNAc glycosylation of PFK1 provides a selective
growth advantage to cancer cells by redirecting carbon flow toward the production of
precursors necessary for DNA and protein biosynthesis, as well as reducing power in the
form of NADPH and GSH to thwart ROS insult. Inhibition of glycolytic enzymes (e.g.,
triosephosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase
M2) via other mechanisms has been shown to lead to re-routing of glucose flux toward
anabolic processes (40-42). Our results suggest that inhibition of PFK1, which functions
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upstream of these enzymes and is a major classical regulatory point for central carbon flow,
exerts profound control over cancer cell metabolism and confers the ability to adapt rapidly
to the changing needs and microenvironment of tumor cells. As blocking PFK1
glycosylation enhances its activity and resets the cellular metabolism toward normal cell
growth, therapeutics that inhibit PFK1 glycosylation or lead to activation of PFK1 may
represent a novel approach to combat cancer.
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Fig. 1. Modulation of O-GlcNAc levels affects cellular metabolism and glycosylation of PFK1
(A) O-GlcNAc glycosylation levels as determined by immunoblotting with an anti-O-
GlcNAc antibody after treatment of H1299 cells with the OGA inhibitor O-(2-acetamido-2-
deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc) or OGT
overexpression. Tubulin levels demonstrate equal protein loading. (B) Glycolytic rate,
lactate production and relative ATP levels in untreated H1299 cells (Cont), PUGNAc-
treated H1299 cells and H1299 cells overexpressing OGT (n = 5). (C) OGT levels in H1299
cells transfected with scramble or OGT shRNA. Tubulin levels demonstrate equal protein
loading. Glycolytic rate, lactate production and relative ATP levels of H1299 cells
transfected with OGT shRNA (kd) upon treatment with or without PUGNAc (n = 4; N.S.,
Not Significant). (D) PFK1 activity in untreated 293T cells (Cont), PUGNAc-treated 293T
cells and 293T cells overexpressing OGT (n = 5). (E) Detection of PFK1 glycosylation by
Western blotting after chemoenzymatic labeling of O-GlcNAc residues with UDP-GalNAz
and the enzyme GalT, followed by reaction with an alkyne-biotin derivative, streptavidin
pull-down and elution of the biotinylated proteins. GalT and UDP-GalNAz were removed as
a control to confirm the specific labeling of O-GlcNAc. (F) Detection of glycosylated PFK1
levels in 293T cells stably expressing Flag-tagged PFK1 by chemoenzymatic labeling with a
5-kDa mass tag and immunoblotting with an anti-Flag antibody. Cells were untreated
(Cont), treated with PUGNAc or transfected to overexpress OGT. (G) PFK1 glycosylation
levels under hypoxic conditions or glucose deprivation. Levels were detected in H1299 cells
stably expressing Flag-tagged PFK1 by chemoenzymatic labeling with a 5-kDa mass tag as
described above. Error bars denote s.e.m. Statistical analysis was performed by Student’s t-
test (* P < 0.05) for all figures.
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Fig. 2. Glycosylation within the F-2,6-BP binding site of PFK1 inhibits its activity and
oligomerization
(A) Peptide sequence and glycosylation site (red) identified by ETD-MS (top). Sequence
alignment of the residues surrounding Ser529 of PFK1 across different species (bottom). (B)
Glycosylation levels of Flag-tagged WT PFK1 and PFK1 mutants as determined by
chemoenzymatic labeling with a 5-kDa PEG mass tag followed by immunoblotting with an
anti-Flag antibody. (C) Homology model of F-2,6-BP (yellow) bound to rabbit PFK1. (D)
Computational model of rabbit PFK1 O-GlcNAc glycosylated (yellow) at Ser530, the
residue equivalent to Ser529 in human PFK1. (E) Relative activities of WT and S529A
PFK1 purified from transfected 293T cells with (High) and without (Low) treatments to
enhance PFK1 glycosylation levels. Activities were measured in the presence of 100 μM
F-2,6-BP and 3 mM ATP and were normalized with respect to the activity of WT PFK1
without treatment (n = 3). (F) Oligomerization state of Flag-tagged PFK1 purified from
untreated 293T cells (Cont), and 293T cells following treatment with PUGNAc or OGT
overexpression. (G) Co-immunoprecipitation of endogenous PFK1 with Flag-tagged WT or
S529A PFK1 following OGT overexpression. Error bars denote s.e.m. Statistical analysis
was performed by Student’s t-test (* P < 0.05) for all figures.
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Fig. 3. PFK1 glycosylation at Ser529 regulates glycolysis, increases PPP flux and protects cells
from ROS-mediated cell death
(A) Immunoblotting of H1299 cells stably expressing shRNA constructs and rescue
constructs. Cells were infected with lentivirus containing shRNA-resistant Flag-WT or
S529A PFK1 constructs where indicated, selected for 2 weeks and then infected with
lentivirus containing scramble or PFK1 shRNA constructs to knockdown endogenous PFK1
expression. Tubulin levels demonstrate equal protein loading. Flag-PFK1 levels were
comparable to endogenous PFK1 levels. (B) Glycolytic rate and lactate production of H1299
knock-in cells expressing WT or S529A PFK1 in the absence (Cont) or presence of OGT
overexpression (n = 4). (C) PPP activity in WT or S529A PFK1 knock-in cells in the
absence (Cont) or presence of OGT overexpression. PPP activity was calculated as the
difference between the rate of [1-14C]-glucose and [6-14C]-glucose oxidation to [14C]-CO2
(n = 3). (D) Percentage of central carbon flux from glucose to lactate flowing through the
PPP in WT or S529A PFK1 knock-in cells in the absence (Cont) or presence of OGT
overexpression. Flux was determined from the relative enrichment of doubly vs. singly
[13C]-labeled lactate, pyruvate, and 3-phosphoglycerate, as measured using negative mode
triple-quadrupole LC-MS of extracts from cells fed with [1,2-13C]-glucose. (E) NADPH and
GSH levels in WT or S529A PFK1 knock-in cells in the absence (Cont) or presence of OGT
overexpression. NADPH levels were measured using a colorimetric assay (BioVison). GSH
levels were measured by fluorimetric detection of the binding of the thiol probe
monochlorobimane to the free GSH. Levels are shown relative to WT PFK1 Cont (n = 4).
(F) NADPH and GSH levels in WT or S529A PFK1 knock-in cells under hypoxic
conditions (n = 3). (G) Cellular ROS levels induced by varying concentrations of diamide in
untreated H1299 cells (Cont) and H1299 cells overexpressing OGT, as measured by
oxidation of the dye CM-H2DCFDA. (H) Percentage of cell death induced by varying
concentrations of hydrogen peroxide in untreated H1299 cells (Cont) and H1299 cells
overexpressing OGT, as measured by media lactate dehydrogenase levels (n = 4). Error bars
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denote s.e.m. Statistical analysis was performed by Student’s t-test (* P < 0.05) for all
figures.
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Fig. 4. Blocking PFK1 glycosylation slows cell proliferation and reduces the tumorigenicity of
lung cancer cells
(A) Cell proliferation rates under hypoxic conditions of WT and S529A PFK1 H1299
knock-in cells with and without OGT overexpression (n = 3; * P < 0.05, N.S., Not
Significant). (B) Cell proliferation rates under hypoxic conditions of H1299 cells infected
with lentiviruses containing scramble or PFK1 shRNA constructs following no treatment
(Cont), OGT knockdown or OGT overexpression (n = 3; * P < 0.05). (C) Tumor formation
in nude mice injected with WT or S529A PFK1 H1299 knock-in cells with and without
OGT overexpression. Dissected tumors after 7-weeks growth in mice injected with WT cells
on the left flank and S529A cells on the right flank (left). Masses of the dissected tumors
(right). Each x represents the tumor mass from one mouse; the blue line indicates the mean
tumor mass. Error bars denote s.e.m. Statistical analysis was performed by Student’s t-test
for all figures.
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